The International Congress on Neuroscience, Brain Health & Mental Wellness (ICNBM 2027) convenes a global community of neuroscientists, psychiatrists, neurologists, psychologists, and mental health innovators to address the most pressing challenges in brain science and mental health today.
From neurodegeneration and cognitive decline to depression, anxiety, and the neurobiology of trauma, ICNBM 2027 explores the full spectrum of brain health through the lens of cutting-edge research, clinical innovation, and emerging therapeutic strategies. Set against the inspiring backdrop of Prague, Czech Republic, the congress creates a dynamic environment for interdisciplinary collaboration, translational science, and global knowledge exchange.
At a time when the global burden of neurological and mental health disorders has never been greater, ICNBM 2027 serves as a critical forum for transforming scientific discovery into meaningful clinical and societal impact.
Distinguished scientists, clinicians, and innovators in neuroscience, psychiatry, and mental health will deliver keynote lectures presenting the most significant advances and emerging paradigms in brain health research. Each keynote is curated to span the breadth of the congress — connecting molecular neuroscience with clinical translation, and basic research with population health impact.
1Scientists and clinicians from research institutions, hospitals, and universities across the globe will present their latest original findings through oral presentations and interactive poster sessions. These forums provide a rigorous and supportive environment for scientific critique, collaborative dialogue, and the formation of research partnerships that advance brain and mental health science.
2Five thematic scientific sessions encompass the full spectrum of neuroscience and mental health — from neurodegeneration, psychiatry, and neuroimaging through to neurodevelopment and emerging therapeutics. Each session is structured to ensure that neurologists, psychiatrists, psychologists, neuroscientists, and allied professionals across every subspecialty find their research area substantively represented.
3Expert-led panel discussions will engage the most urgent and complex questions facing the neuroscience and mental health community — from the translation of biomarker discoveries into clinical practice to the ethical and regulatory dimensions of emerging psychedelic and neuromodulation therapies. These discussions are designed to foster critical thinking and generate insights that transcend individual research disciplines.
5Discover the latest advances in neuroscience research tools, clinical neurotechnology, digital mental health platforms, and therapeutic innovations through our dedicated exhibition space. Engage directly with technology developers, pharmaceutical and biotech organizations, and research institutions to explore solutions that can advance your research and clinical practice.
6ICNBM 2027 creates structured and informal opportunities for neuroscientists, psychiatrists, psychologists, clinicians, and industry professionals to connect, exchange ideas, and develop collaborations. From dedicated networking sessions to social events in the heart of Prague, the congress is designed to build the interdisciplinary relationships that brain health research demands.
6By attending the International Congress on Neuroscience, Brain Health & Mental Wellness 2027, you will immerse yourself in the most current and consequential advances in brain science and mental health, connect with a global community of researchers and clinicians, and contribute to the scientific progress that is transforming how we understand and treat neurological and psychiatric conditions. We look forward to welcoming you to Prague in April 2027.
Focus Areas Include:
Alzheimer's disease — pathology, biomarkers & therapeutics, Parkinson's disease & movement disorders, frontotemporal dementia & Lewy body disease, ALS & motor neuron disease, Huntington's disease, synucleinopathies, multiple sclerosis & neuroimmunology, traumatic brain injury (TBI) & chronic traumatic encephalopathy, stroke & post-stroke cognitive impairment, vascular dementia & cerebrovascular disease, mild cognitive impairment & conversion risk, tau, amyloid & neuroinflammation, fluid biomarkers (CSF, plasma, NfL, p-tau), prion diseases, cognitive reserve & brain aging, caregiving & palliative neurology.
Focus Areas Include:
Focus Areas: Major depressive disorder — neurobiology & epidemiology, bipolar disorder — mechanisms & diagnosis, anxiety disorders, OCD & PTSD, schizophrenia & psychosis spectrum, addiction & substance use disorders, neurobiology of psychiatric illness, inflammation & immune mechanisms in psychiatry, epigenetics & gene-environment interaction in mental health, transdiagnostic & dimensional psychiatry (RDoC), suicidology & crisis intervention, trauma & stress-related disorders, personality disorders, sleep disorders & insomnia, global mental health burden & policy, community psychiatry & mental health access.
Focus Areas Include:
Structural & functional MRI, resting-state & task-based fMRI, diffusion tensor imaging (DTI), PET imaging in neurological disease, EEG, MEG & brain oscillations, brain-computer interfaces & neural decoding, connectomics & neural circuit mapping, graph theory & network neuroscience, computational modeling of brain circuits, neural population dynamics, AI & machine learning in neuroimaging, neurogenetics & gene-brain relationships, brain atlases & large-scale neuro datasets, open neuroscience & data sharing, optogenetics & circuit manipulation, multimodal neuroimaging biomarkers
Focus Areas Include:
Autism spectrum disorder — genetics, detection & intervention, ADHD — neurobiology & management, intellectual disabilities & neurodevelopmental syndromes, genetic neurodevelopmental syndromes (Fragile X, Rett, Down syndrome), childhood epilepsy & pediatric neurology, language, reading & learning disorders, prematurity & neonatal brain injury, early-life stress & developmental programming, early brain development & critical periods, maternal mental health & fetal neurodevelopment, adolescent brain development & risk behavior, adolescent substance use & risk neurobiology, neurodiversity & inclusive education, school-based mental health programs
Focus Areas Include:
Novel antidepressants, antipsychotics & mood stabilizers, ketamine & esketamine therapy, psilocybin, MDMA & psychedelic-assisted therapy, TMS, tDCS & non-invasive neuromodulation, deep brain stimulation & invasive neuromodulation, clinical trials in neuropsychiatry, treatment response biomarkers, pharmacokinetics & pharmacodynamics, combination therapy approaches, safety, adverse effects & long-term outcomes, regulation of neurotechnology, digital therapeutics & mental health apps, telepsychiatry & remote mental health delivery, wearables & passive mental health monitoring, precision psychiatry & biomarker-guided treatment, neuroplasticity-based rehabilitation
ICNBM 2027 — Target Audience
Date: May 31, 2026
Date: October 31, 2026
Date: November 1-30, 2026
Date: January 31, 2027
